AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Teva Pharmaceutical Industries Limited American Depositary Shares
XNYS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S62NT9
41.17▲ 0.07 (0.17%)
As of 2026-10-12
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
41.10
Day's Range
40.60 – 41.49
52-Week Range
18.83 – 42.02
Volume
7.2M
Avg Volume
5.4M
Share Statistics
Shares Outstanding
Employees
32.8K
Exchange
XNYS
Listed
1982-02-16
Share count as of June 30, 2026

Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
What is Teva Pharmaceutical Industries Limited American Depositary Shares's Market Cap?
Teva Pharmaceutical Industries Limited American Depositary Shares's Market Cap is $48.0B, based on as-reported figures from SEC (XBRL) filings.
What is Teva Pharmaceutical Industries Limited American Depositary Shares's Enterprise Value?
Teva Pharmaceutical Industries Limited American Depositary Shares's Enterprise Value is $61.0B, based on as-reported figures from SEC (XBRL) filings.
What is Teva Pharmaceutical Industries Limited American Depositary Shares's Trailing P/E?
Teva Pharmaceutical Industries Limited American Depositary Shares's Trailing P/E is 68.0×, based on as-reported figures from SEC (XBRL) filings.
What is Teva Pharmaceutical Industries Limited American Depositary Shares's Price / Sales?
Teva Pharmaceutical Industries Limited American Depositary Shares's Price / Sales is 2.8×, based on as-reported figures from SEC (XBRL) filings.
What is Teva Pharmaceutical Industries Limited American Depositary Shares's EV / Revenue?
Teva Pharmaceutical Industries Limited American Depositary Shares's EV / Revenue is 3.5×, based on as-reported figures from SEC (XBRL) filings.
What is Teva Pharmaceutical Industries Limited American Depositary Shares's EV / EBITDA?
Teva Pharmaceutical Industries Limited American Depositary Shares's EV / EBITDA is 23.5×, based on as-reported figures from SEC (XBRL) filings.
What is Teva Pharmaceutical Industries Limited American Depositary Shares's Revenue (TTM)?
Teva Pharmaceutical Industries Limited American Depositary Shares's Revenue (TTM) is $17.3B, based on as-reported figures from SEC (XBRL) filings.
What is Teva Pharmaceutical Industries Limited American Depositary Shares's Net Income (TTM)?
Teva Pharmaceutical Industries Limited American Depositary Shares's Net Income (TTM) is $706.0M, based on as-reported figures from SEC (XBRL) filings.
What is Teva Pharmaceutical Industries Limited American Depositary Shares's EBITDA?
Teva Pharmaceutical Industries Limited American Depositary Shares's EBITDA is $2.6B, based on as-reported figures from SEC (XBRL) filings.
What is Teva Pharmaceutical Industries Limited American Depositary Shares's Diluted EPS (TTM)?
Teva Pharmaceutical Industries Limited American Depositary Shares's Diluted EPS (TTM) is 0.61, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · TEVAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Net revenues
YoY growth-0.8%+2.3%+11.4%+3.4%
Cost of sales
Gross profit
% of revenue52.0%49.5%56.4%51.4%
Research and development expenses
Selling and marketing expenses
General and administrative expenses
Intangible assets impairments
Other assets impairments, restructuring and other items
Legal settlements and loss contingencies
Other loss (income)
Operating income (loss)
% of revenue-5.6%16.4%6.4%19.7%
Financial expenses, net
Income (loss) before income taxes
Income taxes (benefit)
Share in (profits) losses of associated companies, net
Net income (loss)
% of revenue-13.9%9.3%10.2%9.7%
Net income (loss) attributable to redeemable and non-redeemable non-controlling interests——
Net income (loss) attributable to Teva
% of revenue-13.9%9.3%10.2%9.7%
Earnings (loss) per share attributable to ordinary shareholders:
Basic
Diluted